Medical Device News Magazine

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

ATLATL Scientific and Miltenyi Biotec are celebrating a landmark five-year partnership, marking a journey of collaboration and innovation in the biotech sector. With a strong foundation laid over the years, this partnership has flourished into a dynamic alliance poised to drive significant advancements in biotechnology.

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources. The collaboration in Singapore builds upon the foundation set by their successful ventures, including the CliniMACS Cell Factory® and the MACS® Innovation & Technology Center, MITC Beijing. As ATLATL Scientific expands its presence into Singapore, Miltenyi Biotec emerges as a key partner, contributing multiple platforms such as CliniMACS Prodigy® and CliniMACS Plus to ATLATL’s incubator at Helios Biopolis. This strategic collaboration underscores Miltenyi Biotec’s commitment to supporting innovative startups and driving technological advancements in the biotech ecosystem.

The partnership between ATLATL Scientific and Miltenyi Biotec was further solidified at AsiaBio 2024, where they co-sponsored the event as booth partners. At the event, both companies signed a Memorandum of Understanding (MOU) to signify their continued partnership and strengthen their ties as they expand their presence in Singapore. This collaboration sets the stage for future joint initiatives aimed at fostering innovation and driving growth in the biotech sector.

Looking ahead, ATLATL Scientific and Miltenyi Biotec are poised to embark on co-research and co-development projects in Singapore. These initiatives will not only bolster both companies’ presence in the local biotech ecosystem but also cement Miltenyi Biotec’s position as a prominent maker of cutting-edge equipment for Cell and Gene Therapy. By combining their strengths and resources, ATLATL Scientific and Miltenyi Biotec aim to drive transformative impact in the biotech industry, both locally and globally.

As they look beyond AsiaBio 2024, ATLATL Scientific and Miltenyi Biotec are committed to further collaborations in different global sites, including China, US, and Europe area. These initiatives underscore their shared vision of driving innovation and advancing biotechnology on a global scale.

The partnership between ATLATL Scientific and Miltenyi Biotec represents a testament to the power of collaboration in driving scientific innovation. As they celebrate five years of partnership, both companies are poised to build upon their achievements and drive even greater impact in the years to come.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”